Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2004-7-21
pubmed:abstractText
Psoriasis is a chronic, immune-mediated disorder that usually requires long-term treatment for control. Approximately 25% of patients have moderate to severe disease and require phototherapy, systemic therapy or both. Despite the availability of numerous therapeutic options, the long-term management of psoriasis can be complicated by treatment-related limitations. With advances in molecular research and technology, several biological therapies are in various stages of development and approval for psoriasis. Biological therapies are designed to modulate key steps in the pathogenesis of psoriasis. Collectively, biologicals have been evaluated in thousands of patients with psoriasis and have demonstrated significant benefit with favourable safety and tolerability profiles. The limitations of current psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of biological therapies into clinical practice are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0007-0963
pubmed:author
pubmed:issnType
Print
pubmed:volume
151 Suppl 69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3-17
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Biological therapies in the systemic management of psoriasis: International Consensus Conference.
pubmed:affiliation
Department of Dermatology and Allergy, University Hospital Charité, Berlin, Germany. wolfram.sterry@charite.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Consensus Development Conference